A collaborative research study, based on survey results gathered by the American Cancer Society, has found a correlation between depressive symptoms in cancer caregivers and a decline in their physical health.
A collaborative research study among researchers at the American Cancer Society, Memorial Sloan Kettering Cancer Center (MSKCC), and the University of Miami has found a correlation between depressive symptoms in cancer caregivers and a decline in their physical health.
The study included data from 664 caregivers (mean age, 53.2 years) across the nation who were classified based on the number of years after their family members’ cancer diagnosis: 2 years (T1), 5 years (T2), and 8 years (T3). These were survey results from the American Cancer Society’s National Quality of Life Survey for Caregivers. The study outcome was physical health of the caregiver, which was assessed from T1 through T3. Self-reporting predictors at T1 included demographics (age, sex, education, income, relationship to patient, and employment status), patient cancer severity, and caregiver psychosocial factors (caregiving stress, caregiving esteem, social support, and depressive symptoms).
While in the early years (T1) caregivers reported slightly better physical health than the control population, this advantage declined over 6 years. A significant determinant of a caregiver’s initial physical health included demographic factors, patient cancer severity, and T1 caregiving stress (P ≤ .03). However, while depressive symptoms were unrelated to the caregiver’s initial physical health, they predicted a decline in health (P = .004).
“Adverse effects of depression on physical health have been well-documented in the general population,” the authors write. “These findings extend evidence to the cancer caregiving context, known to have many psychosocial stressors and challenges, and highlight the importance of depression specifically to caregivers’ premature physical health decline.”
“Identifying caregivers in need, and connecting these caregivers to effective and accessible psychosocial services, are imperative next steps to improve comprehensive care for families facing cancer,” said study author Kelly M. Shaffer, PhD, of MSKCC.
Current and Emerging Options for Uncommon EGFR- and Exon 20 Insertion–Mutated NSCLC
September 8th 2025Uncommon EGFR mutations in non–small cell lung cancer (NSCLC) remain challenging to treat, but new tyrosine kinase inhibitors, bispecific antibodies, and a proposed “PACCage insert” framework provide opportunities to advance precision therapy.
Read More
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Evolving Roles of Antibody-Drug Conjugates in the Treatment of NSCLC
September 7th 2025Antibody-drug conjugates are rapidly reshaping the treatment landscape of non–small cell lung cancer (NSCLC), with advances in design, clinical efficacy, and regulatory approvals tempered by ongoing challenges in toxicity, resistance, and biomarker optimization.
Read More
From Amivantamab to Next-Generation Therapies: The Evolving Bispecific Antibody Landscape in NSCLC
September 6th 2025Bispecific antibodies are emerging as a transformative class in advanced non–small cell lung cancer (NSCLC), with agents such as amivantamab and zenocutuzumab already demonstrating clinical benefit and a broad pipeline of investigational therapies showing promise in overcoming resistance.
Read More